RICO Suit Hits Cresco, GTI, and Verano Over Marketing Claims

A 320-page federal class action naming three of the country’s largest cannabis multi-state operators is prompting new scrutiny from the insurance and legal communities, with analysis published May 18, 2026 by insurance industry publication Claims Journal warning that the suit could reshape how cannabis companies are underwritten and what operators are asked to defend.

The case, Murray et al. v. Cresco Labs Inc. et al., was filed May 4, 2026 in the U.S. District Court for the Northern District of Illinois. More than 40 plaintiffs from 12 states allege that Cresco Labs, Green Thumb Industries, and Verano Holdings marketed adult-use cannabis products as safe and even therapeutic while concealing mounting evidence of health risks. A companion suit targeting Curaleaf Holdings was filed the same day in federal court in Connecticut.

The ‘Big Tobacco’ Theory of Liability

The complaint draws explicit comparisons to the tobacco litigation of the 1990s. Plaintiffs allege that the three operators sponsored favorable research while suppressing evidence linking cannabis use to psychosis, schizophrenia, cardiovascular events, and other conditions — effectively adopting a playbook of promoting wellness benefits for products they knew or should have known posed serious risks. The suit focuses entirely on adult-use purchases; physician-prescribed medical cannabis is carved out.

The legal architecture carries real financial exposure. The complaint is anchored in the federal racketeering statute, which allows plaintiffs to seek treble damages — meaning actual damages could be tripled — plus attorneys’ fees. The Supreme Court’s April 2, 2025 ruling in Medical Marijuana, Inc. v. Horn clarified that civil racketeering claims can extend to economic losses tied to mislabeled cannabis products, strengthening the legal footing for exactly this kind of suit. The complaint layers on consumer-fraud, breach-of-warranty, and negligent-misrepresentation allegations under each plaintiff state’s consumer protection statutes.

The lead attorney, Patrick Kenneally, is a former Illinois county prosecutor. In 2023, he compelled McHenry County dispensaries to post in-store warnings about cannabis-related mental health risks and backed a billboard campaign linking the product to suicide and schizophrenia. An earlier, similar suit against Verano was dismissed in March 2026; the new complaint is longer and more detailed.

Ian Stewart, co-chair of Wilson Elser’s Cannabis Law Practice, wrote in Claims Journal that Murray v. Cresco represents a distinct species of product liability — rooted in marketing conduct rather than a physical product defect. While many cannabis insurance policies carry exclusions for health-hazard claims, class action exposure, and treble-damage awards, Stewart argues that defendants will still tender claims under their general liability, products liability, and directors-and-officers coverage, generating coverage fights that could outlast the underlying litigation.

Verano told industry press the suit “mirrors claims that have been rejected by courts in similar legal actions against multistate operators in the industry earlier this year.” Whether a 320-page complaint built on two decades of scientific literature clears the same threshold remains to be seen. For context on how federal courts have historically handled cannabis racketeering claims, see this MyCannabis piece.

Why Rescheduling Amplifies the Risk

The timing matters. The Department of Justice’s April 22, 2026 order moved state-licensed medical cannabis and FDA-approved products onto Schedule III of the Controlled Substances Act. Greater federal legitimacy is likely to carry greater compliance expectations — on product safety, labeling accuracy, and the health claims operators make to consumers. The more cannabis is treated as a regulated health product, the more its marketers can expect to be held to standards closer to what pharmaceutical and supplement companies face.

That cuts in two directions. Federal recognition opens access to banking, capital markets, and institutional investors that operators have been largely locked out of. It also means health claims that passed without serious challenge in a Schedule I environment may draw closer attention from regulators and plaintiffs’ attorneys in a Schedule III world.

Canada’s Commanding Position in Germany

While U.S. operators wrestle with expanding litigation risk at home, Canadian licensed producers are consolidating their hold on Europe’s largest medical market. Official data from Germany’s Federal Institute for Drugs and Medical Devices (BfArM) shows Canada supplied 26,753 kilograms of the 50,539 kilograms of medical cannabis flower Germany imported in the first quarter of 2026 — a 53% share. Portugal ranked second at 10,342 kilograms; Denmark contributed 3,338 kilograms.

The Q1 2026 total was up 34% from the same quarter a year earlier, though it declined about 15% from Q4 2025, pointing to seasonal softening after a record year. Germany imported more than 201 tonnes in full-year 2025 — nearly triple its 2024 volume.

Canada’s structural position in that market rests partly on a domestic tax advantage: the country’s cannabis excise tax of $1 per gram does not apply to exports, making European sales attractive for licensed producers facing margin compression at home. On May 4, 2026, representatives from Canada’s cannabis sector met with the Parliamentary Secretary to the Minister of International Trade and the Canada Trade Commissioner Service to discuss export market development.

EU-GMP certification remains the mandatory compliance threshold for any cannabis entering German pharmacies. Producers who secured that certification early hold a durable supply-chain advantage. A practice drawing growing regulatory attention — routing non-certified product through certified processors before market entry — could, if curtailed, shake out suppliers who built their Germany position on borrowed compliance infrastructure rather than their own certified facilities.